We have investigated the in vivo efficacy of a systemic gene transfer method, which combines a liposomal delivery system (DLS liposomes) Systemic gene therapy by direct delivery of plasmid DNA coupled to synthetic carriers is appealing because of its simplicity, low toxicity, and potential for multiorgan targeting. Although the efficiency of in vitro transfection of DNA plasmids is limited when compared to delivery by viral vectors, recent advances, especially in liposomal delivery, have demonstrated that nonviral gene transfer offers exciting potential (1, 2). Recent attempts to deliver genetic material have provided an impetus to liposome technology (3-6), in particular formation of complexes of DNA with cationic liposomes (7-11). A few therapeutic clinical trial protocols using local administration of these complexes are ongoing but data on systemic administration are still poorly documented (12, 13) . In this study, we describe a liposomal formulation for gene delivery called DLS, which could be suitable for systemic administration. To obtain long-term expression from a nonintegrated transgene, episomal self-replicating plasmid vectors were constructed and tested. Using the luciferase gene (luc) as a reporter gene (14), we detected transgene expression in various mouse tissues using measurements of luciferase activity, PCR analysis, and immunohistochemistry. Our results demonstrated that a single injection of an episomal DNA vector using the DLS liposome delivery system yielded widespread and long-lasting transgene expression.
Systemic gene therapy by direct delivery of plasmid DNA coupled to synthetic carriers is appealing because of its simplicity, low toxicity, and potential for multiorgan targeting. Although the efficiency of in vitro transfection of DNA plasmids is limited when compared to delivery by viral vectors, recent advances, especially in liposomal delivery, have demonstrated that nonviral gene transfer offers exciting potential (1, 2) . Recent attempts to deliver genetic material have provided an impetus to liposome technology (3) (4) (5) (6) , in particular formation of complexes of DNA with cationic liposomes (7) (8) (9) (10) (11) . A few therapeutic clinical trial protocols using local administration of these complexes are ongoing but data on systemic administration are still poorly documented (12, 13) . In this study, we describe a liposomal formulation for gene delivery called DLS, which could be suitable for systemic administration. To obtain long-term expression from a nonintegrated transgene, episomal self-replicating plasmid vectors were constructed and tested. Using the luciferase gene (luc) as a reporter gene (14) , we detected transgene expression in various mouse tissues using measurements of luciferase activity, PCR analysis, and immunohistochemistry. Our results demonstrated that a single injection of an episomal DNA vector using the DLS liposome delivery system yielded widespread and long-lasting transgene expression.
MATERIALS AND METHODS Materials. Dioctadecylamidoglycylspermidine (7) was generously provided by J. P. Behr DLS liposomes consist of multilamellar bilayer vesicles, which may complex as well as encapsulate DNA. The entrapment rate was found to be 88% ± 8% (mean ± SD) of the initial DNA input dose.
In Vivo Gene Transfer. All procedures were performed in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Plasmid DNA in DLS liposomes was administered by a single injection of 100-600 IlI (total vol) in the tail vein of 4-to 6-week-old female BALB/c mice. Control mice received 150 mM NaCl solution. Mouse tissues were collected in 2-ml Eppendorf tubes, quickly frozen on dry ice, and stored at -70°C until examined.
Detection of Luciferase Activity. Extraction of luciferase from mouse tissues was carried out as described (16) In addition, PCR primers (5'-ATGGATAAAGTTCT-TAACAGGGAA-3' and 5'-GTTATTTTGGGGGTGGTG-TTTTAG-3') encoding the entire large T antigen of BKV were synthesized for amplification of a 2.5-kb sequence. This sequence contains four Dpn I/Mbo I restriction sites, which can be used to determine the episomal state of the plasmid in cells (19) . PCR was performed as described with the following exceptions: 40 cycles of 94°C for 45 sec and 72°C for 2 min in the presence (final concentration) of 1 ,uM primers and 1.25 ,uM dNTPs in 40 ,ul using "hot start" methodology.
Luciferase mRNA transcripts in mouse tissue were detected by reverse transcriptase (RT)-PCR. First RNA was extracted from frozen tissue powder using the Totally RNA isolation kit (Ambion, Austin, TX). RT-PCR was carried out using the rTth DNA polymerase and the GeneAmp RNA-PCR kit (PerkinElmer). Samples for reverse transcription were incubated for 30 min at 60°C. PCR was performed as described above.
Luciferase Immunohistochemical Detection. Mouse tissues were embedded in OC (Miles), quickly frozen, sectioned at 6-8 ,um, and collected on sialinized glass slides. Frozen sections were fixed and endogenous peroxidase was blocked with a 3% hydrogen peroxide solution made up in 100% methanol. Sections were rinsed with running tap water for 2 min and then rinsed three times for 15 min each with 0.2 M phosphate-buffered saline (pH 7.6). Nonspecific protein binding was blocked with protein blocking agent (ShandonLipshaw, Pittsburgh) for 25 min at room temperature. Polyclonal rabbit anti-luciferase antibody (Cortex Biochem, San Leandro, CA) was added at a dilution of 1:300 after protein blocking agent draining off slides and sections was incubated for 1 hr. The slides were rinsed in phosphate-buffered saline and incubated for 30 min with a biotinylated antibody directed against the primary antibody. After rinsing, sections were incubated with an avidin/biotin-labeled streptABC complex (Shandon-Lipshaw) for 30 min. Peroxidase-reactive sites were developed by incubating the slides with the 3-amino-9-ethylcarbazole solution (Shandon-Lipshaw). Sections were then rinsed and counterstained with Gills hematoxylin.
Statistical Analysis. Statistical analyses were performed using Student's t test for comparison of means.
RESULTS
DNA Dose-Response. To assess for treatment-related toxicity and to determine the optimal liposomal DNA amount to be injected, we carried out dose-response experiments. Episomally replicative pBKdlRSV-luc plasmid DNA encapsulated in DLS liposomes was administered i.v. into mice. Luciferase activity was determined 4 days postinjection in liver, lung, and spleen (Fig. 1) . Luciferase activity could be detected in these tissues even when the amount of injected DNA was as low as 25 ,g per mouse. No significant difference in luc gene expression between tissues was observed at this concentration, while at 100 jig of DNA injected per mouse a significant difference in activity was observed between lung, liver, and spleen (1700 ± 100, 1020 ± 300, and 490 ± 130 fg of luciferase per mg of protein, respectively; mean + SD). (Fig. 3) . The recombinant protein was detected in all tissues tested, although the percentage of positive cells varied: heart, >75%; spleen and liver, >50%; colon and lung, >10%. The pattern of transgene expression was generalized throughout the heart (Fig. 3A , vascular endothelial cells and myocytes), liver (Fig. 3B , hepatocytes, Kupfer cells, and endothelial cells), and spleen (data not shown). Although staining intensity was lower in the colon (Fig. 3D) (Fig. 4) . Transgene expression was maximal between 6 and 15 days postinjection in lung, spleen, and heart and then gradually declined over 3 months. Luciferase activity was low and constant for up to 3 months in the liver. No detectable luciferase activity was observed in these tissues 6 months postinjection. Luciferase activity was also detected at 6 and ovary; for up to 2 months in muscle, BMCs, and PB; and for up to 3 months in lung, liver, spleen, and heart. In addition, kidney and colon tissues were positive 2 months postinjection (data not shown). We could not detect the presence of the reporter gene in mouse tissues 6 months postinjection. luc expression was detected by RT-PCR analysis. As shown in Fig. 5 (Upper) , liver, spleen, lung, and heart expressed luciferase mRNA at 2 weeks postinjection, while lung and spleen were positive 3 months postinjection.
Effect of Plasmid Construct and Promoter on Transgene Expression. We compared the expression of six luciferase plasmids in different organs beginning 6 days after a single i.v. injection of 75 jig of DNA delivered with DLS liposomes. The results at 6 days are summarized in Table 2 and show that, when the pRSV-luc plasmid was used, luciferase activity was detected only in lung. In contrast, luciferase activity was high in all tissues tested (liver, lung, spleen, and heart) when pCMVintlux was used. The four BKV-derived episomal plasmids showed slightly less or equivalent reporter gene activity. The CMV promoter yielded significantly higher levels of gene expression in spleen and lower levels in lung when compared with the RSV promoter driving the same plasmid DNA construct. The time course of luc expression in mouse tissues from the nonreplicative pCMVintlux and episomal pBKd2CMV-luc plasmid constructs was followed after a single i.v. injection of 75 ,Ag of DNA (Fig. 3) . luc gene product expressed from pBKd2CMV-luc was detected in lung, liver, spleen, and heart for up to 2-3 months postin- jection. No detection of luciferase activity was observed in these tissues 1 month after injection of pCMVintlux.
Analysis of Episomal Replication in Lung. DNA extracts from lung tissue of mice treated with pBKdlRSV-luc in DLS liposomes and sacrificed 2 weeks after injection were subjected to a PCR-based assay for episomal replication (19) . We observed amplification of the BKV T-antigen targeted sequence after digestion of supernatant DNA by either Dpn I or Mbo I (Fig. 5 Lower). Thus, results revealed that both the original, prokaryoticderived (Mbo I insensitive) and eukaryotic, episomally replicated (Dpn I insensitive) forms of pBKdlRSV-luc were present (lanes 2 and 3, respectively). This is in contrast to the Dpn I sensitivity (lane 5) and Mbo I insensitivity (lane 6) of control prokaryoticderived pBKdlRSV-luc. tpBKdlCMV-luc vs. pBKdlRSV in spleen (P = 0.001).
tpBKd2CMV-luc vs. pBKd2RSV-luc in lung (P = 0.187). §pBKd2CMV-Iuc vs. pBKd2RSV-Iuc in spleen (P = 0.021).
DISCUSSION
The long-term transgene expression observed in this study was shown to be due to the ability of DLS liposomes to deliver significant amounts of DNA in mouse tissues and to the use of BKV-derived episomal expression vectors. Episomal vectors derived from the BKV contain a viral origin of DNA replication and a viral early gene that transactivates the viral DNA origin of replication, allowing for episomal replication in permissive cells (20) . BKV-derived expression vectors share the desirable qualities of extrachromosomal replication and thus a lack of a requirement of cellular division for the chromosomal replication of retroviral-based vectors. Moreover, extrachromosomal expression may lessen the possibility of attenuation of transgene expression due to host cischromosomal effects.
The episomal expression constructs we used improved the persistence of transgene expression when compared with the use of nonepisomal vectors. Using PCR analysis, we were able to detect the transgene in lung, liver, spleen, and heart and the transgene mRNA in lung and spleen for as long as 3 months. In a previous study using a nonepisomal vector (13), the catalase reporter gene was found by PCR analysis in lung, spleen, and heart for up to 2 months postinjection. However, the catalase activity promptly dropped after peaking 2-4 days postinjection and could not be detected after 10-12 days postinjection. In contrast, transgene expression in this report declined slowly after a maximum level between 6 and 15 days postinjection and was detected for up to 3 months in various mouse tissues. Original and episomally replicated forms of BKV-derived vectors were both present in lung tissue 2 weeks postinjection, suggesting episomal replication from this point on. The persistence of extrachromosomal replication of BKVderived vectors in various mouse tissues after systemic administration remains to be investigated.
A degree of tissue-specific expression was observed in our study depending on the liposome preparation, the route of administration, and the promoter driving expression of the transgene. We observed that the more cationic (DNA/lipid ratio, <0.05; wt/wt) the liposomes, the more lung and heart are targeted (results not shown). Although reporter gene expression was lower after s.c. administration of liposomal DNA compared to i.v. administration, there were no changes in tissue targeting. In contrast and as expected, after i.p. administration the spleen was particularly targeted. Immunohistochemical staining and measurement of luciferase activity together indicated organ difference in transgene specific activity. In lung, specific activity was greatest as a result of a high level of fg of luciferase per mg of tissue and low percentage of positive cells. In contrast, liver tissue had low luciferase activity and a high percentage of positive cells, indicating that overall tissue specific activity was low. Our results also demonstrate that the CMV promoter is capable of more efficient expression in spleen than in lung when compared to the RSV promoter. Among various eukaryotic or viral promoters tested, the CMV promoter used in pCMVintlux plasmid appeared to yield the highest luc expression in muscle (16) . Thus, the choice of promoter may greatly influence the efficacy of non-retroviralmediated gene delivery and may lead to a certain degree of tissue specificity.
In this study, we investigated transgene expression after a single injection of liposomal DNA. We may assume that repeated injection might increase and/or prolong transgene expression. Then desirable transgenes could be repetitively administered and thus this offers attractive alternative perspectives to retroviral-mediated gene therapy. However, one must consider the potential of toxicity. As observed in this study and reported previously, neither systemic delivery nor aerosol delivery induced cytotoxicity or immunogenicity when liposomal DNA was administered at doses that produced detectable transgene expression (10, 11, 21) .
We conclude that expression of a transgene through systemic gene transfer via liposomal delivery is efficient and depends on both the liposome preparation and the design of the plasmid expression vector. In this regard, we have illustrated the feasibility and versatility of this combination for systemic gene therapy as an alternative to the treatment of certain human diseases.
